Publication Name	World Journal of Diabetes
Manuscript ID	64302
Country	India

Received	2021-02-15 07:49
Peer-Review Started	2021-02-15 07:54
To Make the First Decision
Return for Revision	2021-03-30 02:29
Revised	2021-04-12 18:36
Second Decision	2021-07-19 03:13
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-07-19 07:56
Articles in Press	2021-07-19 07:56
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-07-28 01:26
Typeset the Manuscript	2021-09-02 01:46
Publish the Manuscript Online	2021-09-07 08:15

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Review
Article Title	Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence
Manuscript Source	Invited Manuscript
All Author List	Ayan Roy, Jayaprakash Sahoo, Niya Narayanan, Chandhana Merugu, Sadishkumar Kamalanathan and Dukhabandhu Naik
Funding Agency and Grant Number
Corresponding Author	Jayaprakash Sahoo, MD, Additional Professor, Department of Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Room No. 5444, 4th Floor, Super Specialty Block, Puducherry 605006, India. jppgi@yahoo.com
Key Words	Autoimmune disease; Bullous pemphigoid; Diabetes; Dipeptidyl peptidase-4 inhibitors; Gliptins; Inflammation
Core Tip	Dipeptidyl peptidase-4 (DPP-4) has an important role in the function of the immune system. DPP-4 inhibitors (DPP-4i) are an important drug class for the management of type 2 diabetes mellitus. This group of drugs can have a diverse effect on the immune modulation. Recently, certain autoimmune diseases are described with the use of DPP-4i, particularly bullous pemphigoid. Clinicians should be aware of this association and take appropriate action if such an adverse event takes place.
Publish Date	2021-09-07 08:15
Citation	Roy A, Sahoo J, Narayanan N, Merugu C, Kamalanathan S, Naik D. Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence. World J Diabetes 2021; 12(9): 1426-1441
URL	https://www.wjgnet.com/1948-9358/full/v12/i9/1426.htm
DOI	https://dx.doi.org/10.4239/wjd.v12.i9.1426

Full Article (PDF)	WJD-12-1426.pdf
Full Article (Word)	WJD-12-1426.docx
Manuscript File	64302-Review-FilipodiaCL.docx
Answering Reviewers	64302-Answering reviewers.pdf
Audio Core Tip	64302-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	64302-Conflict-of-interest statement.pdf
Copyright License Agreement	64302-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	64302-Language certificate.pdf
Peer-review Report	64302-Peer-review(s).pdf
Scientific Misconduct Check	64302-Bing-Wang JL-1.jpg
Scientific Misconduct Check	64302-Bing-Fan JR-2.png
Scientific Misconduct Check	64302-Scientific misconduct check.pdf
Scientific Editor Work List	64302-Scientific editor work list.pdf